Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Imipenem/Relebactam”

17 trials

Showing 17 of 17 results

Not applicableUnknownNCT04196608
What this trial is testing

In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients

Who this might be right for
Ceftolozane/TazobactamImipenem/RelebactamHematology and Oncology
Emilio Bouza 1,005
Large-scale testing (Phase 3)Study completedNCT03293485
What this trial is testing

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)

Who this might be right for
Complicated Intra-abdominal InfectionComplicated Urinary Tract Infection
Merck Sharp & Dohme LLC 83
Large-scale testing (Phase 3)Study completedNCT05204563
What this trial is testing

Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

Who this might be right for
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Evopoint Biosciences Inc. 450
Large-scale testing (Phase 3)Study completedNCT03583333
What this trial is testing

Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)

Who this might be right for
Hospital-Acquired Bacterial PneumoniaVentilator-Associated Bacterial Pneumonia
Merck Sharp & Dohme LLC 274
Testing effectiveness (Phase 2)Study completedNCT04983901
What this trial is testing

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
M.D. Anderson Cancer Center 100
Early research (Phase 1)Study completedNCT04147221
What this trial is testing

Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance

Who this might be right for
Sepsis
Hartford Hospital 9
Large-scale testing (Phase 3)Study completedNCT02493764
What this trial is testing

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

Who this might be right for
Bacterial Pneumonia
Merck Sharp & Dohme LLC 537
Not applicableStudy completedNCT05048693
What this trial is testing

Use of New Antibiotics in Sweden

Who this might be right for
Multi-antibiotic Resistance
Uppsala University 41
Large-scale testing (Phase 3)Study completedNCT03969901
What this trial is testing

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Who this might be right for
Suspected or Documented Gram-negative Bacterial Infection
Merck Sharp & Dohme LLC 115
Testing effectiveness (Phase 2)Study completedNCT01506271
What this trial is testing

Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)

Who this might be right for
Intra-abdominal Infections
Merck Sharp & Dohme LLC 351
Post-approval studies (Phase 4)WithdrawnNCT04785924
What this trial is testing

Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

Who this might be right for
Carbapenem-Resistant Enterobacteriaceae InfectionKPCGram-Negative Bacterial Infections+1 more
Wake Forest University Health Sciences
Not applicableUnknownNCT05285046
What this trial is testing

Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM

Who this might be right for
Bacterial InfectionsAntibiotic Resistant Infection
D'Or Institute for Research and Education 250
Post-approval studies (Phase 4)Ended earlyNCT05561764
What this trial is testing

Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

Who this might be right for
Cystic FibrosisPneumonia, Bacterial
Hartford Hospital 4
Testing effectiveness (Phase 2)Study completedNCT01505634
What this trial is testing

Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)

Who this might be right for
Urinary Tract InfectionsPyelonephritis
Merck Sharp & Dohme LLC 302
Large-scale testing (Phase 3)Study completedNCT02452047
What this trial is testing

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

Who this might be right for
Bacterial Infections
Merck Sharp & Dohme LLC 50
Post-approval studies (Phase 4)WithdrawnNCT05146154
What this trial is testing

Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

Who this might be right for
ObesityCritical Illness
University of Illinois at Chicago
Early research (Phase 1)Study completedNCT04493151
What this trial is testing

Imipenem/Cilastatin/Relebactam PK in ECMO

Who this might be right for
Sepsis
Joseph L. Kuti, PharmD 8

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation